Form 4: Merck Director Christine Seidman Reports Acquisition of Phantom Stock Units Under Pre-Arranged Plan

Merck & Co., Inc. Director Christine E. Seidman reported the acquisition of 102.6402 phantom stock units, which are cash-settled upon termination of service, under a Rule 10b5-1(c) plan.

Summary

• Christine E. Seidman, a Director of Merck & Co., Inc. (MRK), reported changes in her beneficial ownership.
• On June 30, 2025, 102.6402 units of phantom stock were acquired.
• Each phantom stock unit is convertible 1-for-1 into Common Stock, with an acquisition price of $79.16 per unit.
• Phantom stock units are to be settled 100% in cash upon the reporting person's termination of service, in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
• Following the reported transaction, direct beneficial ownership of Common Stock is 100 shares.
• Total beneficial ownership of derivative securities (phantom stock) following the reported transaction is 18,495.8789 units, which includes units acquired through dividend reinvestment.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged strategy for equity management.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock by a director is generally a positive signal, indicating confidence and alignment with shareholder interests, although phantom stock is cash-settled. It's a routine compensation event.

Positives

• The acquisition of phantom stock by a director indicates continued alignment of interests with shareholders, as the value of these units is tied to the company's stock performance.
• The transaction was conducted under a Rule 10b5-1(c) plan, suggesting a pre-planned and systematic approach to equity management, which can reduce concerns about opportunistic insider trading.

Negatives

• Phantom stock units are cash-settled upon termination of service, meaning they do not directly increase the director's equity stake in the company's common stock, but rather represent a deferred cash compensation tied to stock performance.

Future Outlook

The filing primarily reports scheduled insider transactions and does not provide a general future outlook for the company. The phantom stock units are to be settled upon the reporting person's termination of service.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction by a director of a major pharmaceutical company, Merck & Co., Inc. Such transactions are common and reflect individual compensation and investment strategies rather than broader industry trends. The use of phantom stock is a common compensation mechanism in large corporations, particularly for non-employee directors, to align their interests with shareholders without granting direct equity that might complicate tax or regulatory matters.

Comparison to Industry Standards

• The acquisition of phantom stock by a director is a standard practice for executive and director compensation in large, publicly traded companies like Merck.
• Phantom stock plans are widely used across various industries, including pharmaceuticals, as a form of deferred compensation that ties payouts to company stock performance.
• For instance, companies like Pfizer (PFE) and Johnson & Johnson (JNJ) also utilize various forms of equity-based compensation, including restricted stock units or phantom stock, for their directors and executives to align their interests with long-term shareholder value.
• The specific value of $79.16 per phantom stock unit reflects the market price at the time of acquisition, which is typical for such grants.

Stakeholder Impact

• Shareholders: The director's increased beneficial ownership (even if phantom) aligns interests, potentially signaling confidence in the company's future performance.

Next Steps

• Phantom stock units are to be settled 100% in cash upon the reporting person's termination of service.

Key Dates

Recommendation

Keywords

Merck & Co., MRK, SEC Form 4, Insider Transaction, Director Compensation, Phantom Stock, Equity Acquisition, Rule 10b5-1, Christine E. Seidman